Plasma phosphorylated tau 217 in preclinical Alzheimer’s disease
Brain Communications · 2023-03-02 · 5 (2)
DOI: 10.1093/braincomms/fcad057 ↗At a glance
Journal article in Brain Communications, published online on 2023-03-06. Written by Erin M Jonaitis and 11 co-authors. Institution: Wisconsin Alzheimer's Institute, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53726, USA. Cited 128 times so far (Crossref); 50 references. The full text is freely available (open access, CC BY 4.0). Funded by: NIA NIH HHS, NIH HHS, NCATS NIH HHS.
Topics: Demenz
Abstract (original language)
An accurate blood test for Alzheimer’s disease that is sensitive to preclinical proteinopathy and cognitive decline has clear implications for early detection and secondary prevention. We assessed the performance of plasma phosphorylated tau 217 (pTau217) against brain PET markers of amyloid [[11C]-labelled Pittsburgh compound B (PiB)] and tau ([18F]MK-6240) and its utility for predicting longitudinal cognition. Samples were analysed from a subset of participants with up to 8 years follow-up in the Wisconsin Registry for Alzheimer’s Prevention (WRAP; 2001–present; plasma 2011–present), a longitudinal cohort study of adults from midlife, enriched for parental history of Alzheimer’s disease. Participants were a convenience sample who volunteered for at least one PiB scan, had usable banked plasma and were cognitively unimpaired at first plasma collection. Study personnel who interacted with participants or samples were blind to amyloid status. We used mixed effects models and receiver–operator characteristic curves to assess concordance between plasma pTau217 and PET biomarkers of Alzheimer’s disease and mixed effects models to understand the ability of plasma pTau217 to predict longitudinal performance on WRAP’s preclinical Alzheimer’s cognitive composite (PACC-3). The primary analysis included 165 people (108 women; mean age = 62.9 ± 6.06; 160 still enrolled; 2 deceased; 3 discontinued). Plasma pTau217 was strongly related to PET-based estimates of concurrent brain amyloid (β^ = 0.83 (0.75, 0.90), P < 0.001). Concordance was high between plasma pTau217 and both amyloid PET (area under the curve = 0.91, specificity = 0.80, sensitivity = 0.85, positive predictive value = 0.58, negative predictive value = 0.94) and tau PET (area under the curve = 0.95, specificity = 1, sensitivity = 0.85, positive predictive value = 1, negative predictive value = 0.98). Higher baseline pTau217 levels were associated with worse cognitive trajectories (β^pTau×age = −0.07 (−0.09, −0.06), P < 0.001). In a convenience sample of unimpaired adults, plasma pTau217 levels correlate well with concurrent brain Alzheimer’s disease pathophysiology and with prospective cognitive performance. These data indicate that this marker can detect disease before clinical signs and thus may disambiguate presymptomatic Alzheimer’s disease from normal cognitive ageing.
Subjects
Author keywords
Authors and institutions
- Wisconsin Alzheimer's Institute, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53726, USA.
- Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53792, USA.
- Department of Medicine, Division of Geriatrics and Gerontology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53792, USA.
- Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund 205 02, Sweden.
- Department of Biostatistics and Medical Informatics, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53726, USA.
- Department of Neurology, Skåne University Hospital, Lund 222 42, Sweden.
ORCID profiles: Karly A Cody, Lianlian Du, Niklas Mattsson-Carlgren, Tobey J Betthauser, Oskar Hansson
Funding
- NIA NIH HHS
- NIH HHS
- NCATS NIH HHS
- National Institutes of Health
- Alzheimer’s Association Research Foundation
- University of Wisconsin Institute for Clinical and Translational Research
- Swedish Research Council
- Knut and Alice Wallenberg foundation
Cite
APA
Jonaitis, E. M., Janelidze, S., Cody, K. A., Langhough, R., Du, L., Chin, N. A., Mattsson-Carlgren, N., Hogan, K. J., Christian, B. T., Betthauser, T. J., Hansson, O., & Johnson, S. C. (2023). Plasma phosphorylated tau 217 in preclinical Alzheimer’s disease. Brain Communications, 5(2). https://doi.org/10.1093/braincomms/fcad057
Vancouver
Jonaitis EM, Janelidze S, Cody KA, Langhough R, Du L, Chin NA, et al. Plasma phosphorylated tau 217 in preclinical Alzheimer’s disease. Brain Communications. 2023;5(2). doi:10.1093/braincomms/fcad057
BibTeX
@article{Jonaitis2023,
author = {Jonaitis, Erin M and Janelidze, Shorena and Cody, Karly A and Langhough, Rebecca and Du, Lianlian and Chin, Nathaniel A and Mattsson-Carlgren, Niklas and Hogan, Kirk J and Christian, Bradley T and Betthauser, Tobey J and Hansson, Oskar and Johnson, Sterling C},
title = {Plasma phosphorylated tau 217 in preclinical Alzheimer’s disease},
journal = {Brain Communications},
year = {2023},
volume = {5},
number = {2},
doi = {10.1093/braincomms/fcad057}
}
EUVIMED